Brainpower for Brainpower

     Eli Lilly & Co. (LLY) recognizes the immense financial burden placed upon them by government regulators who force the company to conduct enormously expensive, unnecessary tests before they will permit a new drug to be put on the market.  This creates a situation where patients must pay many times as much as they otherwise would have to if pharmaceutical companies were left alone to send new medicines along an economical course.  Government also coerces companies into granting some individuals a "free ride" which drives up costs even more.  This regulation by government is not only immoral, it damages the prospects for future medicines and cures.

In my own life, I worked for the money that I paid Eli Lilly for their psychiatric medicine, Zyprexa, at full price, for many years.  When I discovered a path to reduce the financial burden, I directed much of my free time towards blogging for Lilly as a thank you.  If you take time to look at my blogs, you may agree with me that Eli Lilly & Co. (LLY) has been paid many times over for their government pressured "philanthropy".

In this blog, my latest idea is to create a program of voluntary trade, at Eli Lilly, by applying my model of "ideas for medicine" towards Lilly's upcoming, blockbuster Alzheimer's drug, Solanezumab.  It could work like this.  Eli Lilly & Co. could create a program in which some at-risk individuals would use their minds to brainstorm for ideas and ways to help Eli Lilly.  Lilly could set up a panel to evaluate ideas as they come in and award the best ones months of earned Solanezumab.  Since the nature of Alzheimer's is that it is a progressive cognitive decline, by applying brainpower now, a talented mind would store up defensive countermeasures for a better future.  In this way, businessmen and intellectuals could team up to improve Eli Lilly & Co. (LLY) and create the products of talented thought at the same time.

Paul Wharton
Special thanks to Eli Lilly & Co. (LLY)